IDH1 and cancer: Given the fact that the induction of PD-L1 overexpression is negatively associated with patient OS, and this characteristic has been linked to resistance to anticancer therapies in other human cancers (Wang et al., 2016; Wu et al., 2016; Xu et al., 2016), further understanding of the overexpression of PD-L1 by IDH1 wildtype tumors would provide a useful clinical reference that could be employed to stratify patients to ensure proper use of PD1/PD-L1 blockers in radio/chemo-resistant IDH wildtype gliomas.